Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065137 | 0.82 | CHRM1 (0.42) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL715079 | 0.77 | — | — | |
| SCHEMBL3830276 | 0.77 | TSHR (0.50) | TSHR | |
| SCHEMBL3083369 | 0.74 | — | — | |
| SCHEMBL15786467 | 0.74 | — | — | |
| SCHEMBL2721371 | 0.74 | — | — | |
| SCHEMBL18422068 | 0.74 | CHRM1 (0.33) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL14742948 | 0.72 | — | — | |
| SCHEMBL20796785 | 0.72 | TSHR (0.33) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL9657425 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4377322-A1 | PROCESS FOR THE MANUFACTURING OF A GADOLINIUM COMPLEX SOLUTION | Bracco Imaging SPA (IT) | 2024-06-05 | — | — | EP | claimed |
| CN-117440959-A | Method for producing gadolinium complex solutions | 伯拉考成像股份公司 | 2024-01-23 | — | — | CN | claimed |
| WO-2023006722-A1 | PROCESS FOR THE MANUFACTURING OF A GADOLINIUM COMPLEX SOLUTION | BRACCO IMAGING SPA (IT) | 2023-02-02 | — | — | WO | claimed |
| US-11021451-B2 | Contrast agents | BRACCO IMAGING S.P.A. (IT) | 2021-06-01 | — | — | US | claimed |
| EP-3753929-A1 | DIMERIC CONTRAST AGENTS | Bracco Imaging SPA (IT) | 2020-12-23 | — | — | EP | claimed |
| EP-3386954-B1 | DIMERIC CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2020-12-02 | — | — | EP | claimed |
| US-20200325108-A1 | CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2020-10-15 | — | — | US | claimed |
| US-10407412-B2 | Dimeric contrast agents | BRACCO IMAGING S.P.A. (IT) | 2019-09-10 | — | — | US | claimed |
| US-20180362511-A1 | DIMERIC CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2018-12-20 | — | — | US | claimed |
| US-20180362476-A1 | CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2018-12-20 | — | — | US | claimed |
| EP-3386953-A1 | CONTRAST AGENTS | Bracco Imaging SpA (IT) | 2018-10-17 | — | — | EP | claimed |
| EP-3386954-A1 | DIMERIC CONTRAST AGENTS | Bracco Imaging SpA (IT) | 2018-10-17 | — | — | EP | claimed |
| WO-2017098044-A1 | DIMERIC CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2017-06-15 | — | — | WO | claimed |
| WO-2017098038-A1 | CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2017-06-15 | — | — | WO | claimed |
| EP-0116566-B1 | NEW D-MANNITE DERIVATIVES AS STARTING PRODUCTS FOR THE SYNTHESIS OF PHOSPHOLIPIDS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1988-06-08 | — | — | EP | claimed |
| US-4734225-A | ANTITUMOR AGENTS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1988-03-29 | — | — | US | claimed |
| EP-0116566-A1 | NEW D-MANNITE DERIVATIVES AS STARTING PRODUCTS FOR THE SYNTHESIS OF PHOSPHOLIPIDS. | MAX PLANCK GESELLSCHAFT (DE) | 1984-08-29 | — | — | EP | claimed |
| WO-1984000362-A2 | NEW D-MANNITE DERIVATIVES AS STARTING PRODUCTS FOR THE SYNTHESIS OF PHOSPHOLIPIDS | MAX PLANCK GESELLSCHAFT (DE) | 1984-02-02 | — | — | WO | claimed |
| EP-0098600-A2 | D-mannitol derivatives as starting materials in the synthesis of phospholipids | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1984-01-18 | — | — | EP | claimed |
| CN-113423470-B | Cosmetic compounding agent, cosmetic, and method for producing same | 三吉油脂株式会社 | 2024-07-09 | — | — | CN | disclosed |
| EP-4377322-A1 | PROCESS FOR THE MANUFACTURING OF A GADOLINIUM COMPLEX SOLUTION | Bracco Imaging SPA (IT) | 2024-06-05 | — | — | EP | disclosed |
| US-20240057587-A1 | ORGANIC AMMONIUM SALT AND HYDROGEN-BONDING MATERIAL TREATMENT AGENT USING SAME | MIYOSHI OIL & FAT CO.,LTD. (JP) | 2024-02-22 | — | — | US | disclosed |
| CN-117440959-A | Method for producing gadolinium complex solutions | 伯拉考成像股份公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117203308-A | Additive for making interface active and emulsifying composition using the same | 三吉油脂株式会社 | 2023-12-08 | — | — | CN | disclosed |
| US-20230340356-A1 | ADDITIVE OR COMPOSITION FOR IMPARTING LUBRICITY | MIYOSHI OIL & FAT CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| EP-3766969-B1 | BIOCATALYST SOLVENT USING IONIC LIQUID, AND BIOCATALYST SOLUTION CONTAINING BIOCATALYST AND SAID SOLVENT | MIYOSHI YUSHI KK (JP) | 2023-10-04 | — | — | EP | disclosed |
| US-11700852-B2 | Aqueous electrolyte-containing adjuvant compositions, active ingredient-containing compositions and the use thereof | CLARIANT INTERNATIONAL LTD (CH) | 2023-07-18 | — | — | US | disclosed |
| EP-3621437-B1 | USE OF N-ALKYL GLUCAMIDES FOR REDUCING DRIFT DURING THE APPLICATION OF GLUFOSINATE-CONTAINING PLANT TREATMENT AGENTS | CLARIANT INT LTD (CH) | 2023-07-12 | — | — | EP | disclosed |
| EP-4166635-A1 | ADDITIVE OR COMPOSITION FOR IMPARTING LUBRICITY | Miyoshi Oil & Fat Co., Ltd. (JP) | 2023-04-19 | — | — | EP | disclosed |
| CN-115702231-A | Additives or compositions for imparting lubricity | 三吉油脂株式会社 | 2023-02-14 | — | — | CN | disclosed |
| WO-2023006722-A1 | PROCESS FOR THE MANUFACTURING OF A GADOLINIUM COMPLEX SOLUTION | BRACCO IMAGING SPA (IT) | 2023-02-02 | — | — | WO | disclosed |
| EP-3556211-B1 | ORGANIC AMMONIUM SALTS OF ANIONIC PESTICIDES | CLARIANT INT LTD (CH) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022181381-A1 | ORGANIC AMMONIUM SALT HAVING PHOSPHONATE OR PHOSPHINATE ANION, AND COMPOSITION WHICH IS CAPABLE OF FORMING SAID SALT | ミヨシ油脂株式会社 | 2022-09-01 | — | — | WO | disclosed |
| CN-114728885-A | Organic ammonium salt and hydrogen bonding material treatment agent using same | 三吉油脂株式会社 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022128184-A1 | MINIEMULSIONS COMPRISING SUPERHYDROPHOBIC AND/OR HYDROPHOBIC MONOMERS, METHOD OF PREPARING THE SAME AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2022-06-23 | — | — | WO | disclosed |
| EP-4015541-A1 | MINIEMULSIONS COMPRISING SUPERHYDROPHOBIC AND/OR HYDROPHOBIC MONOMERS, METHOD OF PREPARING THE SAME AND USE THEREOF | Clariant International Ltd (CH) | 2022-06-22 | — | — | EP | disclosed |
| CN-108290849-B | Contrast agents | 伯拉考成像股份公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2021256448-A1 | ADDITIVE OR COMPOSITION FOR IMPARTING LUBRICITY | ミヨシ油脂株式会社 | 2021-12-23 | — | — | WO | disclosed |
| EP-3925671-A1 | COSMETIC INGREDIENT, COSMETIC, AND PRODUCTION METHOD FOR COSMETIC | Miyoshi Oil & Fat Co., Ltd. (JP) | 2021-12-22 | — | — | EP | disclosed |
| EP-3925672-A1 | COMPOSITION CONTAINING ORGANIC AMMONIUM SALT | Miyoshi Oil & Fat Co., Ltd. (JP) | 2021-12-22 | — | — | EP | disclosed |
| US-11160770-B2 | Compounds, compositions and methods for treating oxidative DNA damage disorders | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| CN-110621156-B | Use of N-alkylglucamides for reducing drift when applying plant treatment agents containing glufosinate | 科莱恩国际有限公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-113423470-A | Cosmetic compounding agent, cosmetic and method for producing same | 三吉油脂株式会社 | 2021-09-21 | — | — | CN | disclosed |
| CN-113423800-A | Compositions comprising organic ammonium salts | 三吉油脂株式会社 | 2021-09-21 | — | — | CN | disclosed |
| CN-107205379-B | Aqueous adjuvant composition containing electrolyte, composition containing active ingredient and use thereof | 科莱恩国际有限公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-107072192-B | Organic ammonium salts of anionic pesticides | 科莱恩国际有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-11021451-B2 | Contrast agents | BRACCO IMAGING S.P.A. (IT) | 2021-06-01 | — | — | US | disclosed |
| WO-2021095398-A1 | ORGANIC AMMONIUM SALT AND HYDROGEN BOND MATERIAL TREATING AGENT USING SAME | ミヨシ油脂株式会社 | 2021-05-20 | — | — | WO | disclosed |
| US-20210024500-A1 | DIMERIC CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2021-01-28 | — | — | US | disclosed |
| EP-3766969-A1 | BIOCATALYST SOLVENT USING IONIC LIQUID, AND BIOCATALYST SOLUTION CONTAINING BIOCATALYST AND SAID SOLVENT | Miyoshi Oil & Fat Co., Ltd. (JP) | 2021-01-20 | — | — | EP | disclosed |
| US-10882849-B2 | Dimeric contrast agents | BRACCO IMAGING S.P.A. (IT) | 2021-01-05 | — | — | US | disclosed |
| EP-3753929-A1 | DIMERIC CONTRAST AGENTS | Bracco Imaging SPA (IT) | 2020-12-23 | — | — | EP | disclosed |
| EP-3745859-A1 | COMPOSITIONS COMPRISING WATER-SOLUBLE HERBICIDES AND USE THEREOF | Clariant International Ltd (CH) | 2020-12-09 | — | — | EP | disclosed |
| EP-3386954-B1 | DIMERIC CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2020-12-02 | — | — | EP | disclosed |
| US-20200367504-A1 | Compositions Comprising Water-Soluble Herbicides And Use Thereof | CLARIANT INTERNATIONAL LTD. (CH) | 2020-11-26 | — | — | US | disclosed |
| US-20200331893-A9 | DIMERIC CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2020-10-22 | — | — | US | disclosed |
| EP-3386953-B1 | CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2020-10-21 | — | — | EP | disclosed |
| EP-3130670-B1 | BIOCATALYST SOLVENT USING IONIC LIQUID, AND BIOCATALYST SOLUTION CONTAINING BIOCATALYST AND SAID SOLVENT | MIYOSHI YUSHI KK (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-20200325108-A1 | CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2020-10-15 | — | — | US | disclosed |
| US-10781188-B2 | Contrast agents | BRACCO IMAGING S.P.A. (IT) | 2020-09-22 | — | — | US | disclosed |
| US-10772324-B2 | Aqueous adjuvant-compositions | CLARIANT INTERNATIONAL LTD. (CH) | 2020-09-15 | — | — | US | disclosed |
| US-10759749-B2 | Therapeutic agent for diabetes | JCR PHARMACEUTICALS CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| WO-2020166678-A1 | COSMETIC INGREDIENT, COSMETIC, AND PRODUCTION METHOD FOR COSMETIC | ミヨシ油脂株式会社 | 2020-08-20 | — | — | WO | disclosed |
| WO-2020166674-A1 | COMPOSITION CONTAINING ORGANIC AMMONIUM SALT | ミヨシ油脂株式会社 | 2020-08-20 | — | — | WO | disclosed |
| EP-3694324-A1 | ACTIVE INGREDIENT COMPOSITIONS COMPRISING N-ALKENOYL-N-ALKYLGLUCAMIDES AND THE USE THEREOF | Clariant International Ltd (CH) | 2020-08-19 | — | — | EP | disclosed |
| US-20200215001-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OXIDATIVE DNA DAMAGE DISORDERS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-07-09 | — | — | US | disclosed |
| CN-111200933-A | Active ingredient compositions comprising N-enoyl-N-alkylglucamides and their use | 科莱恩国际有限公司 | 2020-05-26 | — | — | CN | disclosed |
| EP-3621437-A1 | USE OF N-ALKYL GLUCAMIDES FOR REDUCING DRIFT DURING THE APPLICATION OF GLUFOSINATE-CONTAINING PLANT TREATMENT AGENTS | Clariant International Ltd (CH) | 2020-03-18 | — | — | EP | disclosed |
| US-20200060266-A1 | Use Of N-Alkyl Glucamides For Reducing Drift During The Application Of Glufosinate-Containing Plant Treatment Agents | CLARIANT INTERNATIONAL LTD. (CH) | 2020-02-27 | — | — | US | disclosed |
| CN-110621156-A | Use of N-alkylglucamides for reducing drift when applying plant treatment agents containing glufosinate | 科莱恩国际有限公司 | 2019-12-27 | — | — | CN | disclosed |
| US-20190352563-A1 | Surfactant Concentrates For Promoting Soil Humidification And Plant Growth | CLARIANT INTERNATIONAL LTD. (CH) | 2019-11-21 | — | — | US | disclosed |
| US-20190345142-A1 | DIMERIC CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2019-11-14 | — | — | US | disclosed |
| US-10407616-B2 | Surfactant concentrates for promoting soil humidification and plant growth | CLARIANT INTERNATIONAL LTD (CH) | 2019-09-10 | — | — | US | disclosed |
| US-10407412-B2 | Dimeric contrast agents | BRACCO IMAGING S.P.A. (IT) | 2019-09-10 | — | — | US | disclosed |
| WO-2019149514-A1 | COMPOSITIONS COMPRISING WATER-SOLUBLE HERBICIDES AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2019-08-08 | — | — | WO | disclosed |
| EP-3520860-A1 | QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES | Indiana University Research & Technology Corporation (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3508474-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR Pharmaceuticals Co., Ltd. (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR PHARMACEUTICALS CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
| WO-2019072804-A1 | ACTIVE INGREDIENT COMPOSITIONS COMPRISING N-ALKENOYL-N-ALKYLGLUCAMIDES AND THE USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2019-04-18 | — | — | WO | disclosed |
| US-20190110472-A1 | ACTIVE INGREDIENT COMPOSITIONS COMPRISING N-ALKENOYL-N-ALKYLGLUCAMIDES AND THE USE THEREOF | CLARIANT INTERNATIONAL, LTD. (CH) | 2019-04-18 | — | — | US | disclosed |
| US-10240141-B2 | Biocatalyst solvent using ionic liquid, and biocatalyst solution containing biocatalyst and said solvent | MIYOSHI OIL & FAT CO., LTD. (JP) | 2019-03-26 | — | — | US | disclosed |
| EP-2718255-B1 | QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES | UNIV INDIANA RES & TECH CORP (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20180362511-A1 | DIMERIC CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2018-12-20 | — | — | US | disclosed |
| US-20180362476-A1 | CONTRAST AGENTS | BRACCO IMAGING S.P.A. (IT) | 2018-12-20 | — | — | US | disclosed |
| US-10154973-B2 | Quinone compounds for treating APE1 mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-12-18 | — | — | US | disclosed |
| EP-3386954-A1 | DIMERIC CONTRAST AGENTS | Bracco Imaging SpA (IT) | 2018-10-17 | — | — | EP | disclosed |
| EP-3386953-A1 | CONTRAST AGENTS | Bracco Imaging SpA (IT) | 2018-10-17 | — | — | EP | disclosed |
| WO-2018134760-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING AN OXAZINE DERIVATIVE AND ITS USE IN THE TREATMENT OR PREVENTION OF ALZHEIMER'S DISEASE | NOVARTIS AG (CH) | 2018-07-26 | — | — | WO | disclosed |
| US-20180192644-A1 | Aqueous Electrolyte-Containing Adjuvant Compositons, Active Ingredient-Containing Compositions And The Use Thereof | CLARIANT INTERNATIONAL LTD. (CH) | 2018-07-12 | — | — | US | disclosed |
| US-20180133175-A1 | QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES | APEXIAN PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-9877936-B2 | Quinone compounds for treating Ape1 mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170304222-A1 | Compounds, Compositions and Methods for Treating Oxidative DNA Damage Disorders | INDIANA UNIV AND RES TECH CORP (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170265477-A1 | Aqueous Adjuvant Composition Containing Glufosinate | CLARIANT INTERNATIONAL LTD. (CH) | 2017-09-21 | — | — | US | disclosed |
| US-20170231223-A1 | Organic Ammonium Salts Of Anionic Pesticides | CLARIANT INTERNATIONAL LTD. (CH) | 2017-08-17 | — | — | US | disclosed |
| WO-2017098044-A1 | DIMERIC CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017098038-A1 | CONTRAST AGENTS | BRACCO IMAGING SPA (IT) | 2017-06-15 | — | — | WO | disclosed |
| US-20170071199-A1 | Low-Foam Agrochemical Compositions | CLARIANT INTERNATIONAL LTD. (CH) | 2017-03-16 | — | — | US | disclosed |
| US-20170055524-A1 | Aqueous Adjuvant Composition For Increasing The Efficacy Of Electrolyte Active Substances | CLARIANT INTERNATIONAL LTD. (CH) | 2017-03-02 | — | — | US | disclosed |
| US-20170044434-A1 | Surfactant Concentrates For Promoting Soil Humidification And Plant Growth | CLARIANT INTERNATIONAL LTD. (CH) | 2017-02-16 | — | — | US | disclosed |
| EP-3130670-A1 | BIOCATALYST SOLVENT USING IONIC LIQUID, AND BIOCATALYST SOLUTION CONTAINING BIOCATALYST AND SAID SOLVENT | Miyoshi Oil & Fat Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20170029801-A1 | BIOCATALYST SOLVENT USING IONIC LIQUID, AND BIOCATALYST SOLUTION CONTAINING BIOCATALYST AND SAID SOLVENT | MIYOSHI OIL & FAT CO., LTD. (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20160166521-A1 | Compounds, Compositions and Methods for Treating Oxidative DNA Damage Disorders | INDIANA UNIVERSITY AND RES TECHNOLOGY CORP (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160045461-A1 | QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES | APEXIAN PHARMACEUTICALS, INC. | 2016-02-18 | — | — | US | disclosed |
| US-9193700-B2 | Quinone compounds for treating Ape1 mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150320037-A1 | Aqueous Adjuvant-Compositions | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-11-12 | — | — | US | disclosed |
| EP-2794576-A1 | NON-SYSTEMIC TGR5 AGONISTS | Ardelyx, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20140128398-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OXIDATIVE DNA DAMAGE DISORDERS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2014-05-08 | — | — | US | disclosed |
| EP-2723722-A1 | 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL (2,3,4,5,6-PENTAHYDROXYHEXYL) AMINO) ETHOXY) PHENYL) BUTYL) CARBAMIMIDOYL) PYRAZINE-2-CARBOXAMIDE | Parion Sciences, Inc. (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-2718255-A1 | QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES | Indiana University Research and Technology Corporation (US) | 2014-04-16 | — | — | EP | disclosed |
| WO-2013096771-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-8435973-B2 | 17-beta HSD1 and STS inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| WO-2012167122-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OXIDATIVE DNA DAMAGE DISORDERS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012162589-A1 | QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20110021480-A1 | 17-beta HSD1 and STS Inhibitors | SOLVAY PHARMACEUTICALS GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-1930338-A1 | Fumaric acid derivates and ophtalmic lenses using the same | E-brain Corporation Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20080132666-A1 | Fumaric Acid Derivatives and Ophthalmic Lenses Using the Same | MENICON NECT CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1259535-B1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| WO-2005005463-A1 | ANTIFUNGAL CYCLIC LIPOPEPTIDES | ASTELLAS PHARMA INC. (JP) | 2005-01-20 | — | — | WO | disclosed |
| US-20050014685-A1 | New compound | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| US-20050004014-A1 | Fungicides, microbiocides; glucanase inhibitor; prophylaxis, therapy for pneumocystis infections in humans, animals | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| WO-2004113368-A1 | CYCLIC LIPOPEPTIDES | ASTELLAS PHARMA INC. (JP) | 2004-12-29 | — | — | WO | disclosed |
| US-20040231558-A1 | Has a clear hue, high light fastness and high moisture resistance | MITSUI CHEMICALS, INC. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1441013-A1 | WATERCOLOR INK | Mitsui Chemicals, Inc. (JP) | 2004-07-28 | — | — | EP | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | ASTELLAS PHARMA INC. (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1259535-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
| WO-2001060846-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| EP-0514588-B1 | Novel phosphobetaine and detergent and cosmetic containing the same | KAO CORP (JP) | 1997-06-11 | — | — | EP | disclosed |
| EP-0352218-A2 | Macrocyclic polyaza compounds containing rings with 5 or 6 members, methods for their preparation and pharmaceutical compositions containing same | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-01-24 | — | — | EP | disclosed |
| US-4804789-A | D-mannite derivatives as starting products for the synthesis of phospholipids | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1989-02-14 | — | — | US | disclosed |
| EP-0116566-B1 | NEW D-MANNITE DERIVATIVES AS STARTING PRODUCTS FOR THE SYNTHESIS OF PHOSPHOLIPIDS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1988-06-08 | — | — | EP | disclosed |
| US-4734225-A | ANTITUMOR AGENTS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1988-03-29 | — | — | US | disclosed |
| EP-0098600-A2 | D-mannitol derivatives as starting materials in the synthesis of phospholipids | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1984-01-18 | — | — | EP | disclosed |
| US-4418015-A | Phthalocyanine reactive dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1983-11-29 | — | — | US | disclosed |
| EP-0053320-A2 | Process for the preparation of phthalocyanin compounds | BAYER AG (DE) | 1982-06-09 | — | — | EP | disclosed |
| EP-0047863-A2 | Reactive phthalocyanine hyes, process for their preparation and their use in dyeing materials containing hydroxyle groups and/or nitrogen | BAYER AG (DE) | 1982-03-24 | — | — | EP | disclosed |
| US-4311692-A | HYDROXY AMINE SALTS, FATTY ALCHOL, SKIN AND HAIR CARE | QUAD CHEMICAL CORPORATION (US) | 1982-01-19 | — | — | US | disclosed |
| US-4281201-A | WAXY SOLIDS USED AS EMULSIFIERS IN HAIR CONDITIONERS, HAND LOTIONS, AND OTHER TOILETRIES | QUAD CHEMICAL CORPORATION (US) | 1981-07-28 | — | — | US | disclosed |
| US-3989692-A | PHTHALOCYANINE DYES, WOOL, SILK, POLYAMIDES, CELLULOSE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-02 | — | — | US | disclosed |
| US-3989692-A | PHTHALOCYANINE DYES, WOOL, SILK, POLYAMIDES, CELLULOSE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (42 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | CHRM1 424/4885AKR1A1 601/4885CHRM3 1297/4885 |
| US-20200215001-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OXIDATIVE DNA DAMAGE DISORDERS | OGG1, UNG, ERCC4 | CHRM1 4595/4885AKR1A1 743/4885CHRM3 4379/4885 |
| US-20080132666-A1 | Fumaric Acid Derivatives and Ophthalmic Lenses Using the Same | FAH, FH, AQP4 | CHRM1 4531/4885AKR1A1 119/4885CHRM3 4494/4885 |
| US-10240141-B2 | Biocatalyst solvent using ionic liquid, and biocatalyst solution containing biocatalyst and said solvent | BCKDK, HACL2, HAO2 | CHRM1 1765/4885AKR1A1 140/4885CHRM3 2393/4885 |
| US-20200331893-A9 | DIMERIC CONTRAST AGENTS | CALCOCO2, NOD2, SLC39A14 | CHRM1 3407/4885AKR1A1 4129/4885CHRM3 3487/4885 |
| US-11021451-B2 | Contrast agents | SLC39A14, ABCB7, SLC40A1 | CHRM1 2876/4885AKR1A1 3908/4885CHRM3 2429/4885 |
| US-10882849-B2 | Dimeric contrast agents | CALCOCO2, NOD2, SLC39A14 | CHRM1 3407/4885AKR1A1 4129/4885CHRM3 3487/4885 |
| US-20180362511-A1 | DIMERIC CONTRAST AGENTS | CALCOCO2, NOD2, SLC39A14 | CHRM1 3407/4885AKR1A1 4129/4885CHRM3 3487/4885 |
| US-20210024500-A1 | DIMERIC CONTRAST AGENTS | CALCOCO2, NOD2, SLC39A14 | CHRM1 3407/4885AKR1A1 4129/4885CHRM3 3487/4885 |
| US-20190345142-A1 | DIMERIC CONTRAST AGENTS | CALCOCO2, NOD2, SLC39A14 | CHRM1 3407/4885AKR1A1 4129/4885CHRM3 3487/4885 |
| US-20190110472-A1 | ACTIVE INGREDIENT COMPOSITIONS COMPRISING N-ALKENOYL-N-ALKYLGLUCAMIDES AND THE USE THEREOF | B3GNT2, GANAB, GBA2 | CHRM1 1288/4885AKR1A1 200/4885CHRM3 2330/4885 |
| US-20140128398-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OXIDATIVE DNA DAMAGE DISORDERS | OGG1, UNG, ERCC4 | CHRM1 4595/4885AKR1A1 743/4885CHRM3 4379/4885 |
| US-20050014685-A1 | New compound | MAN2B1, MAN2A1, MANBA | CHRM1 395/4885AKR1A1 1328/4885CHRM3 1793/4885 |
| US-20200325108-A1 | CONTRAST AGENTS | SLC39A14, ABCB7, SLC40A1 | CHRM1 2876/4885AKR1A1 3908/4885CHRM3 2429/4885 |
| US-20200060266-A1 | Use Of N-Alkyl Glucamides For Reducing Drift During The Application Of Glufosinate-Containing Plant Treatment Agents | GBA2, GBA1, ASNS | CHRM1 1714/4885AKR1A1 813/4885CHRM3 3081/4885 |
| US-20170304222-A1 | Compounds, Compositions and Methods for Treating Oxidative DNA Damage Disorders | OGG1, UNG, ERCC4 | CHRM1 4595/4885AKR1A1 743/4885CHRM3 4379/4885 |
| US-20180362476-A1 | CONTRAST AGENTS | SLC30A5, SLC39A14, ABCB7 | CHRM1 2829/4885AKR1A1 3959/4885CHRM3 2614/4885 |
| US-10407616-B2 | Surfactant concentrates for promoting soil humidification and plant growth | GBA1, AQP1, GLB1 | CHRM1 577/4885AKR1A1 817/4885CHRM3 1955/4885 |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | NGLY1, ALG1, CHIT1 | CHRM1 1335/4885AKR1A1 1502/4885CHRM3 1783/4885 |
| US-11700852-B2 | Aqueous electrolyte-containing adjuvant compositions, active ingredient-containing compositions and the use thereof | AQP1, PHOSPHO1, AQP3 | CHRM1 3340/4885AKR1A1 2012/4885CHRM3 842/4885 |
| US-20240057587-A1 | ORGANIC AMMONIUM SALT AND HYDROGEN-BONDING MATERIAL TREATMENT AGENT USING SAME | OR10J3, HCN4, CLIC4 | CHRM1 3893/4885AKR1A1 1162/4885CHRM3 4166/4885 |
| US-20190352563-A1 | Surfactant Concentrates For Promoting Soil Humidification And Plant Growth | GBA1, AQP1, GLB1 | CHRM1 577/4885AKR1A1 817/4885CHRM3 1955/4885 |
| US-20170265477-A1 | Aqueous Adjuvant Composition Containing Glufosinate | ASNS, UGGT1, B3GAT3 | CHRM1 653/4885AKR1A1 925/4885CHRM3 1246/4885 |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | GPR119, IAPP, DPP4 | CHRM1 3136/4885AKR1A1 1687/4885CHRM3 3017/4885 |
| US-20200367504-A1 | Compositions Comprising Water-Soluble Herbicides And Use Thereof | ARSA, ABCG2, SULT2A1 | CHRM1 1316/4885AKR1A1 120/4885CHRM3 1442/4885 |
| US-10781188-B2 | Contrast agents | SLC39A14, ABCB7, SLC40A1 | CHRM1 2876/4885AKR1A1 3908/4885CHRM3 2429/4885 |
| US-20150320037-A1 | Aqueous Adjuvant-Compositions | GBA1, MGAM, GLS | CHRM1 207/4885AKR1A1 766/4885CHRM3 64/4885 |
| US-20160166521-A1 | Compounds, Compositions and Methods for Treating Oxidative DNA Damage Disorders | OGG1, UNG, ERCC4 | CHRM1 4488/4885AKR1A1 783/4885CHRM3 4127/4885 |
| US-10154973-B2 | Quinone compounds for treating APE1 mediated diseases | NQO1, APEX1, KEAP1 | CHRM1 4823/4885AKR1A1 724/4885CHRM3 4843/4885 |
| US-10759749-B2 | Therapeutic agent for diabetes | GPR119, IAPP, DPP4 | CHRM1 2564/4885AKR1A1 1257/4885CHRM3 2968/4885 |
| US-11160770-B2 | Compounds, compositions and methods for treating oxidative DNA damage disorders | OGG1, UNG, ERCC4 | CHRM1 4595/4885AKR1A1 743/4885CHRM3 4379/4885 |
| US-20110021480-A1 | 17-beta HSD1 and STS Inhibitors | STS, HSD17B11, HSD17B1 | CHRM1 4235/4885AKR1A1 105/4885CHRM3 4525/4885 |
| US-20170231223-A1 | Organic Ammonium Salts Of Anionic Pesticides | HCN3, HCN4, KCNH3 | CHRM1 12/4885AKR1A1 90/4885CHRM3 17/4885 |
| US-20170055524-A1 | Aqueous Adjuvant Composition For Increasing The Efficacy Of Electrolyte Active Substances | ASNS, ARG1, PHOSPHO1 | CHRM1 1399/4885AKR1A1 1593/4885CHRM3 1184/4885 |
| US-20050004014-A1 | Fungicides, microbiocides; glucanase inhibitor; prophylaxis, therapy for pneumocystis infections in humans, animals | MAN2B1, MAN2A1, MANBA | CHRM1 186/4885AKR1A1 770/4885CHRM3 766/4885 |
| US-20160045461-A1 | QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES | NQO1, APEX1, KEAP1 | CHRM1 4808/4885AKR1A1 774/4885CHRM3 4825/4885 |
| US-10772324-B2 | Aqueous adjuvant-compositions | GBA1, MGAM, GLS | CHRM1 207/4885AKR1A1 766/4885CHRM3 64/4885 |
| US-20170071199-A1 | Low-Foam Agrochemical Compositions | DDOST, GBA1, GBA2 | CHRM1 1926/4885AKR1A1 1888/4885CHRM3 2655/4885 |
| US-20180133175-A1 | QUINONE COMPOUNDS FOR TREATING APE1 MEDIATED DISEASES | NQO1, APEX1, KEAP1 | CHRM1 4823/4885AKR1A1 724/4885CHRM3 4843/4885 |
| US-20180192644-A1 | Aqueous Electrolyte-Containing Adjuvant Compositons, Active Ingredient-Containing Compositions And The Use Thereof | BCHE, CA3, AQP1 | CHRM1 2618/4885AKR1A1 2412/4885CHRM3 365/4885 |
| US-10407412-B2 | Dimeric contrast agents | CALCOCO2, NOD2, SLC39A14 | CHRM1 3407/4885AKR1A1 4129/4885CHRM3 3487/4885 |
| US-20170029801-A1 | BIOCATALYST SOLVENT USING IONIC LIQUID, AND BIOCATALYST SOLUTION CONTAINING BIOCATALYST AND SAID SOLVENT | BCKDK, HACL2, HAO2 | CHRM1 1765/4885AKR1A1 140/4885CHRM3 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.